Full-spectrum hemp-derived CBD and drug testing: what you need to know


Full-spectrum CBD is a powerful wellness tool because it is a whole-plant extraction chockful of cannabinoids and terpenes, producing the widely-touted entourage effect. However, an integral component of this therapeutic arsenal is THC, the notorious sister cannabinoid that produces the “high” of Cheech and Chong repute. Though hemp-derived full-spectrum CBD contains less than 0.3% THC by definition, ENFLEUR would like to address a concern for those subject to drug testing: is it possible to have a false positive on a drug test after taking a full spectrum CBD product?

The short answer is “yes”, because anything is possible. However, if you do your due diligence as a consumer, it is extremely unlikely. Here are some of the reasons why:

-       If you are taking a 30ml, 1,000mg full-spectrum hemp-derived sublingual CBD tincture, less than 0.3% THC content by volume is present at a rate of .09mg for every 33.33mg (a dropperful a day) of product. 

-       Drug testing for the presence of THC or THC metabolites differs in terms of what quantity of THC might signal a positive result. Hair tests target chronic THC use, so if you don’t use recreational cannabis and you don’t have the bankroll or will to consume liters of hemp-derived CBD on a regular basis, you should be in the clear.

-       Fluid, or more popular urine tests, are more sensitive to THC detection. However, the wellness subsidiary of Vice News quotes postdoctoral fellow at the National University of Natural Medicine and founder of the Center for Medical Cannabis Education Jamie Corroon as stating that, in terms of a false positive for THC use when taking a hemp-derived CBD product, “It’s possible, but it’s highly unlikely.”

-       The variable in terms of THC detection from a hemp-derived CBD product depends, in part, on the quantity of consumption as well as the metabolism of the consumer. However, properly vetted hemp-derived CBD greatly reduces the risk of a false positive. Forbes recently covered a case of a woman who tested positive for THC who had never before used marijuana, but had been taking CBD for two weeks prior to a pre-employment drug screening. Why did this happen? The article goes on to state that insufficient consumer vetting leads to the consumption of CBD products that are not above board in terms of THC content. Synthetic cannabinoids or companies that do not invest in chemical analysis sell products with unchecked cannabis constituents. Therefore, an unsuspecting consumer may purchase what they take to be a legitimate and legal CBD product, however, in the as of yet unregulated space of CBD, they are consuming a product with an unknown amount of THC. This obstacle, however, is overcome simply by purchasing hemp-derived full-spectrum CBD from a source that is 100% transparent in terms of its batch-specific certificates of analysis (COAs).

Ultimately, so long as you choose to take a high-quality, full-spectrum CBD product, it is a reasonable, but calculated risk. The odds are overwhelmingly in your favor if you purchase from a company that shares its COAs, you can be assured of the actual quantity of THC. Occurring in the trace amounts of hemp-derived CBD that it does, it is extremely unlikely that THC will trip a false positive on a drug test.

Why does this matter? Proper vetting of quality, transparent hemp-derived CBD makes false positives unlikely.